This Viewpoint aims to provide an understanding of the current contrast in reimbursement for cancer treatment modalities in the US.
No takes yet. Share an insight, caveat, or question.
Chirag Shah (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: